Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Adcendo logo — Development of highly differentiated first-in-class antibody...

Adcendo

Development of highly differentiated first-in-class antibody-drug conjugates (ADCs) for treatment of solid tumors.

Founded 2017 Denmark Denmark 52 employees B Total: $243.00M Biotechnology, Health Care

General Information

Company Name Adcendo
Founded Year 2017
Location Denmark Denmark
Founders / Decision Makers
Team member
Employees 52
Industries Biotechnology, Health Care
Funding Stage B
Social

BounceWatch is an independent company data service, not affiliated with Adcendo. To contact Adcendo, visit adcendo.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

About Adcendo

Adcendo is a biotechnology startup based in Copenhagen, Denmark that focuses on the development of antibody-drug conjugates for creating innovative medicines to address the significant unmet needs of cancer patients. Founded in 2017, the company emerged as a spin-out from The Finsen Laboratory of Rigshospitalet and the University of Copenhagen. In its latest funding round on 29 May 2024, Adcendo secured a substantial €16.00M Series A investment from a notable group of investors including Novo Holdings, Pontifax, RA Capital Management, Gilde Healthcare, HealthCap, Ysios Capital, and Dawn Biopharma. With its commitment to pioneering advancements in healthcare, Adcendo is poised to make a significant impact in the biotechnology sector.

Taxonomy: Biotech, Antibody-drug conjugates, Cancer treatment, Drug development, Copenhagen, Denmark, Finsen Laboratory, Rigshospitalet, University of Copenhagen, Spin-out company, Anti-cancer drugs, Novel targets, Overexpressed targets, Unmet medical need, Research and development

Funding Rounds & Investors (6)

View All
Funding Stage Amount Investors Lead Investors Date
B $135.00M 13
Novo Holdings RA Capital Management Gilde Healthcare
Novo Holdings, RA Capital Management +11
25 Nov 2024
Series A €16.00M 7
Novo Holdings Pontifax RA Capital Management
Novo Holdings, Pontifax +5
29 May 2024
Series A €31.00M 3
Novo Holdings RA Capital Management HealthCap
Novo Holdings, RA Capital Management +1
04 Apr 2023
Series A €51.00M -
29 Apr 2021
Debt Financing kr10.00M -
29 Aug 2019
Grant Undisclosed -
01 Jan 2018

Latest News

View All
Kanser tedavisine odaklanan sağlık girişimi Adcendo, 135 milyon dolar yatırım aldı — Webrazzi
Kanser tedavisine odaklanan sağlık girişimi Adcendo, 135 milyon dolar yatırım aldı
Webrazzi Nov 25, 2024

Adcendo Alternatives & Competitors

View All Alternatives
Adcendo vs
Valink Therapeutics
Valink Therapeutics United States

Making better ADCs

Seed
31 employees
Biotechnology, Health Care
Adcendo vs
ImmunoBiochem Corporation
ImmunoBiochem Corporation Canada

Improving patient outcomes through innovations in biological therapeutics

Seed
4 employees
Biotechnology, Health Care
Adcendo vs
ONA Therapeutics
ONA Therapeutics Spain

First-in-class ADCs tailored to attack advanced cancer

Series A
35 employees
Biotechnology, Health Care
Also compare with: Adcendo vs Eureka Therapeutics, Inc Eureka Therapeutics, Inc View all alternatives

FAQ About Adcendo

Development of highly differentiated first-in-class antibody-drug conjugates (ADCs) for treatment of solid tumors.
Adcendo was founded in 2017.
Adcendo is headquartered in Denmark.
Adcendo operates in Biotechnology and Health Care. Its work centres on Biotech, Antibody-drug conjugates, Cancer treatment and Drug development.
Adcendo has approximately 52 employees.
Adcendo has completed 6 funding rounds, raising a total of $243.00M. The latest funding stage is B.
Top alternatives and competitors to Adcendo include Valink Therapeutics, ImmunoBiochem Corporation, ONA Therapeutics, Novelogics Biotechnology Inc., Biomed Valley Discoveries. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Adcendo and Valink Therapeutics are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Adcendo, https://bouncewatch.com/company/adcendo, updated 30 December 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes